A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, which we refer to collectively as our Candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, or Duchenne, SGT-212 for the treatment of Friedreich's ataxia, or FA, SGT-501 for the treatment of Catecholaminergic polymorphic ventricular tachycardia, or CPVT, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, or TNNT2 DCM, and additional assets for the treatment of genetic cardiac and other diseases, at different stages of development, with varying levels of investment. We are advancing our diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, our mission is to improve the daily lives of patients living with these devastating diseases.
| Metric | TTM | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 0 | 0 | 0 |
| Net Income | -167M | -86M | -72M | -88M | -117M | -75M |
| EPS | $-2.48 | $-10.10 | $-10.14 | $-25.50 | $-43.65 | $-33.75 |
| Free Cash Flow | -133M | -101M | -79M | -57M | -97M | -78M |
| ROIC | -85.6% | -40.6% | -34.7% | -66.6% | -1989.5% | -59.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.23 | 0.12 | 0.00 | 0.01 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -170M | -106M | -72M | -88M | -119M | -76M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -76.7% | -41.0% | -34.7% | -66.8% | -146.4% | -59.8% |
| Shares Outstanding | 78M | 9M | 7M | 3M | 3M | 2M |
| Metric | 2017 | 2018 | 2019 | 2020 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0 | 0 | 0 | 0 | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -55M | -76M | -119M | -88M | -72M | -106M | -170M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -39M | -75M | -117M | -88M | -72M | -86M | -167M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 1.9M | 0 | 7.2M | 7.2M |
| Returns on Capital | |||||||
| ROIC | -60.6% | -59.3% | N/M | -66.6% | -34.7% | -40.6% | -85.6% |
| ROE | -60.6% | -59.8% | -146.4% | -66.8% | -34.7% | -41.0% | -76.7% |
| ROA | -51.6% | -53.6% | -113.3% | -51.6% | -31.1% | -34.9% | -61.0% |
| Cash Flow | |||||||
| Op. Cash Flow | -43M | -70M | -93M | -57M | -78M | -98M | -132M |
| Free Cash Flow | -46M | -78M | -97M | -57M | -79M | -101M | -133M |
| Owner Earnings | -49M | -78M | -110M | -72M | -94M | -108M | -142M |
| CapEx | 2.3M | 7.8M | 4.4M | 899K | 1.3M | 3.0M | 792K |
| Maint. CapEx | 448K | 1.6M | 2.8M | 3.9M | 3.0M | 2.4M | 2.4M |
| Growth CapEx | 1.8M | 6.2M | 1.6M | 0 | 0 | 607K | 0 |
| D&A | 448K | 1.6M | 2.8M | 3.9M | 3.0M | 2.4M | 2.4M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 5.3M | 6.0M | 14M | 12M | 13M | 7.5M | 7.5M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | -86M | -75M | -154M | N/A | N/A | -61M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | 61M |
| Long-Term Debt | N/A | 859K | 733K | 525K | N/A | N/A | N/A |
| Debt/Equity | 0.17 | 0.01 | 0.01 | 0.00 | 0.12 | 0.23 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | 65M | 125M | 80M | 132M | 208M | 212M | 218M |
| Total Assets | 76M | 140M | 103M | 171M | 232M | 260M | 274M |
| Total Liabilities | 11M | 14M | 23M | 39M | 24M | 49M | 56M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -124M | -199M | -316M | -405M | -477M | -563M | -563M |
| Working Capital | 59M | 116M | 68M | 134M | 199M | 197M | 197M |
| Current Assets | 71M | 129M | 86M | 159M | 223M | 220M | 220M |
| Current Liabilities | 11M | 12M | 18M | 24M | 24M | 23M | 23M |
| Per Share Data | |||||||
| EPS | -43.20 | -33.75 | -43.65 | -25.50 | -10.14 | -10.10 | -2.48 |
| Owner EPS | -53.84 | -35.07 | -40.87 | -20.84 | -13.22 | -12.68 | -1.83 |
| Book Value | 71.33 | 56.48 | 29.81 | 38.15 | 29.25 | 24.86 | 2.80 |
| Cash Flow/Share | -47.49 | -31.67 | -34.52 | -16.35 | -10.92 | -11.51 | -2.11 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.9M | 2.2M | 2.7M | 3.5M | 7.1M | 8.5M | 77.9M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -3.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 6.9 | 2.2 | 2.6 | 0.9 | 0.2 | 2.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -9.0% | -56.3% | -16.7% | -42.3% | -216.1% | -20.8% |
| Market Cap | N/A | 865M | 172M | 345M | 187M | 47M | 641M |
| Avg. Price | N/A | 443.54 | 147.29 | 47.55 | 62.99 | 11.43 | 8.23 |
| Year-End Price | N/A | 390.15 | 64.20 | 99.60 | 26.25 | 5.49 | 8.23 |
Solid Biosciences Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Solid Biosciences Inc. (SLDB) has a 5-year average return on invested capital (ROIC) of -50.3%. This is below average and may indicate limited pricing power.
Solid Biosciences Inc. (SLDB) has a market capitalization of $641M. It is classified as a small-cap stock.
Solid Biosciences Inc. (SLDB) does not currently pay a regular dividend.
Solid Biosciences Inc. (SLDB) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Solid Biosciences Inc. (SLDB) generated $-101 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Solid Biosciences Inc. (SLDB) has a debt-to-equity ratio of 0.23. This indicates a conservatively financed balance sheet.
Solid Biosciences Inc. (SLDB) reported earnings per share (EPS) of $-10.10 in its most recent fiscal year.
Solid Biosciences Inc. (SLDB) has a return on equity (ROE) of -41.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for Solid Biosciences Inc. (SLDB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Solid Biosciences Inc. (SLDB) has a book value per share of $24.86, based on its most recent annual SEC filing.